Valuation: SurModics

Market Cap 427M 372M 346M 317M 600M 40.8B 609M 4.08B 1.6B 20.31B 1.6B 1.57B 68.1B P/E 2023
-292x
P/E 2024 -47.3x
Enterprise Value 420M 366M 340M 312M 590M 40.14B 599M 4.01B 1.57B 19.98B 1.58B 1.54B 67.01B EV / Sales 2023
3.33x
EV / Sales 2024 4.33x
Free-Float
99.63%
Yield 2023 *
-
Yield 2024 -
1 year 25.87
Extreme 25.87
43
3 years 25.17
Extreme 25.17
43
5 years 16
Extreme 16
62.27
10 years 16
Extreme 16
82.35
Manager TitleAgeSince
Chief Executive Officer 67 19/11/2025
Director of Finance/CFO 53 19/11/2025
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 67 19/11/2025
Director/Board Member 53 19/11/2025
Date Insider Type Main position Quantity % Market Cap.
11/19/25 A Issuer sale

Director

35,847 0.2507%
11/19/25 A Issuer sale

Controller/Auditor

24,311 0.1700%
11/19/25 A Issuer sale

Director

51,877 0.3628%
Change 5-day change 1-year change 3-year change Capi.($)
+0.35%-.--%+14.83%+33.81% 615M
-0.18%+2.29%-16.46%-5.30% 183B
-0.40%+2.64%-5.35%-2.68% 110B
-0.28%+0.78%+9.17%+67.11% 60.75B
+3.50%-0.66%+30.35%+55.04% 50.01B
-0.18%+5.68%-7.30%-40.69% 45.59B
-0.36%+0.23% - - 33.08B
+11.21%+15.31%+2.14%-33.77% 28.76B
+0.39%+3.68%+42.22%-7.55% 23.9B
-0.73%+7.14%+1.26%+1.69% 22.53B
Average +1.34%+3.92%+7.87%+7.52% 55.77B
Weighted average by Cap. +0.69%+5.47%-1.42%+4.99%

Financials

2023 2024
Net sales 133M 115M 107M 98.49M 186M 12.66B 189M 1.26B 496M 6.3B 498M 487M 21.13B 126M 110M 102M 93.66M 177M 12.04B 180M 1.2B 472M 5.99B 473M 463M 20.09B
Net income -1.54M -1.34M -1.24M -1.14M -2.15M -147M -2.19M -14.65M -5.75M -73M -5.77M -5.64M -245M -11.54M -10.03M -9.34M -8.57M -16.19M -1.1B -16.44M -110M -43.2M -549M -43.35M -42.39M -1.84B
Net Debt -12.1M -10.52M -9.79M -8.99M -16.98M -1.16B -17.24M -115M -45.3M -575M -45.45M -44.45M -1.93B -6.87M -5.97M -5.56M -5.1M -9.64M -656M -9.79M -65.52M -25.72M -326M -25.8M -25.23M -1.09B
Logo SurModics
Surmodics, Inc. is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. It also develops and commercializes highly differentiated vascular intervention medical devices that are designed to address unmet clinical needs and engineered to the demanding requirements. Its segments include Medical Device and IVD. Medical Device segment manufactures and licenses performance coatings, including surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device, with end markets that include neurovascular, peripheral and coronary. IVD segment manufactures chemical and biological components used in in vitro diagnostic immunoassay and molecular tests within the diagnostic and biomedical research markets.
Employees
389
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. SRDX Stock